ClinicalTrials.gg
Active, not recruitingNCT05933200Updated Sep 17, 2026

A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD

A Phase 3 interventional study of Triheptanoin and MCT Oil in Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), sponsored by Ultragenyx Pharmaceutical Inc. Active, not recruiting at 15 sites in 7 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Ultragenyx Pharmaceutical Inc · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2023, registered Jun 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Study summary

The main goal of this study is to evaluate the effects of triheptanoin versus Medium-chain Triglycerides (MCT) on frequency of Major Clinical Events (MCEs).

Read the detailed description

Participants will be randomly assigned 1:1 to receive triheptanoin or MCT oil. The duration of the study is estimated to be 3.5 to 4 years. The study comprises the following: Screening Period, Baseline (Month 0), Double-blind Treatment Period (including Titration and End of Study Visit), Safety Follow-up Phone Visit, and an Open Access Period.

In addition, a substudy will examine the effect of triheptanoin versus MCT on decreasing liver fat fraction to avoid or improve steatosis in subjects with LC-FAOD. Participants older than 2 years of age at selected sites will be invited to screen for the Liver Substudy.

02

Conditions studied

  • Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Browse trials for

Keywords

  • Carnitine Palmitoyl Transferase (CPT) I Deficiency
  • Carnitine Palmitoyl Transferase (CPT) II Deficiency
  • Carnitine/acylcarnitine Translocase (CACT) Deficiency
  • Very Long Chain Acyl-coenzyme A Dehydrogenase (VLCAD) Deficiency
  • Long-chain 3-hydroxyacyl-coenzyme A Dehydrogenase (LCHAD) Deficiency
  • Mitochondrial Trifunctional Protein (TFP) Deficiency
03

In context

VLCAD deficiency

26 studies on the registry are indexed under VLCAD deficiency; 6 are open to participants now.

This study's enrollment of 69 is above the median of 13 across 15 interventional studies indexed under VLCAD deficiency.

Browse VLCAD deficiency studies →

Lead sponsor

Ultragenyx Pharmaceutical Inc is the lead sponsor of 63 studies on the registry; 8 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 12 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Main Study:

  • Males and females, from 0 (including newborns) to \< 18 years of age at time of randomization
  • Confirmed diagnosis of LC-FAOD
  • Have a caregiver(s) willing and able to assist in all applicable study requirements
  • Have a legally authorized representative willing and able to provide written after the nature of the study has been explained and prior to any research-related procedures, and the study participant to be able to provide age-appropriate written assent
  • Have ANY ONE of the following significant clinical manifestations of LC-FAOD:

    • At least 2 in the prior year, or 3 in the prior 2 years, of severe major episodes of metabolic decompensation (eg, hypoglycemia, rhabdomyolysis, or exacerbation of cardiomyopathy, requiring ER/urgent care unit visits or hospitalizations)
    • Recurrent symptomatic hypoglycemia (clinical symptoms of hypoglycemia) requiring intervention
    • Susceptibility to hypoglycemia after short periods of fasting (less than 4 to 12 hours, depending on age)
    • Evidence of functional cardiomyopathy requiring ongoing medical management or clinical manifestation of heart failure
    • Sibling(s) with the same pathogenic variant who presented with MCEs
    • Participant with pathogenic variants that are known or suspected to be associated with absent or severely reduced enzyme activity or with severe disease manifestations.
  • From the period following informed consent to 5 days after the last dose of study drug, females of and fertile males must consent to use highly effective . If female, agree not to become pregnant. If male, agree not to father a child or donate sperm

Inclusion Criteria for Liver Substudy:

  • Enrollment in the Main Study of Study UX007-CL302
  • Age > 2 years
  • Liver fat content ≥ 2% and \< 20% PDFF as assessed by 1 H-MRS
  • \< 95th percentile
  • Able to comply with instructions (remaining still during scan) and requirements (eg, constraints on recent meals, no metallic items or implanted devices in the body, no recent contrast agents) for liver 1 H-MRS scan

Exclusion Criteria for Main Study:

  • Enrolled in a clinical study involving concurrent use of an drug product within 30 days before Screening
  • Use of a prohibited medication (eg, valproate products or pancreatic lipase inhibitors) within 30 days before Screening, or unwilling to avoid a prohibited medication or other substance that may confound study objectives
  • Treatment with triheptanoin within 60 days of Screening
  • History of known to triheptanoin or MCT or its that, in the judgement of the Investigator, places the subject at increased risk for adverse effects
  • Caregiver unwilling or unable to sign informed consent, or release of medical records, or follow study procedures
  • Have any comorbid conditions, including unstable major organ-system disease(s), that in the opinion of the Investigator places the subject at increased risk of complications, interferes with study participation or compliance, or confounds study objectives or interpretation of results. History of metabolic decompensation(s) with metabolic acidosis, hyperammonemia, and/or liver enzyme elevations does not constitute an exclusion criterion unless in the opinion of the Investigator places the subject at increased risk of complications, interferes with study participation or compliance, or confounds study objectives or interpretation of results.
  • Have a diagnosis of pancreatic insufficiency
  • Pregnant, breastfeeding, or planning to become pregnant (self or partner) at any time during the study

Exclusion Criteria for Liver Substudy:

  • Acute or chronic liver disease other than LC-FAOD that presents with increased risk of liver fat (eg, hepatic cirrhosis, viral toxic or drug hepatitis, diabetes mellitus) and/or metabolic syndrome
  • Need for anesthesia/sedation to perform liver 1 H-MRS
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Triheptanoin

    Participants will be given prescriptions for triheptanoin in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. Triheptanoin will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period. Following the Double-blind Treatment Period, open-label triheptanoin will be provided at participants' current dose during an Open Access Period, if no other options to receive trihepatnoin are available locally.

    Drug: Triheptanoin

  • Active comparator
    MCT

    Participants will be given prescriptions for MCT in mL/day, which will be divided into approximately 4 administrations per day, with precise instructions for administration. MCT will be titrated up to the first 6 weeks of the study. After titration, the dose is to remain stable for the remainder of the Double-blind Treatment Period. Following the Double-blind Treatment Period, open-label triheptanoin will be provided at participants' current dose during an Open Access Period, if no other options to receive trihepatnoin are available locally.

    Dietary Supplement: MCT Oil

Interventions

  • Liquid for oral (PO) or enteral feeding tube administration

    Also known as: UX007, Dojolvi

  • Dietary supplementMCT Oil

    Liquid for oral (PO) or enteral feeding tube administration

    Also known as: Medium-chain Triglyceride

06

What researchers measure

Primary outcomes

  1. Annualized Event Rate of Major Clinical Events (MCEs)

    Time frame: Up to Year 4

Secondary outcomes

  1. Annualized Duration of MCEs

    Time frame: Up to Year 4

  2. Annualized Hypoglycemic Event-rate Captured as MCEs and At-home Clinical Events (HCEs)

    Time frame: Up to Year 4

  3. Clinical Global Impression of Change [CGI-C] Scale Score

    Time frame: Up to Year 4

  4. Change From Baseline in Left Ventricular Ejection Fraction

    Time frame: Baseline, Up to Year 1

  5. Change From Baseline in Left Ventricular Systolic Volume

    Time frame: Baseline, Up to Year 1

  6. Change From Baseline in Left Ventricular Wall Mass

    Time frame: Baseline, Up to Year 1

  7. Liver Substudy (Single Study Site Only): Change from Baseline to 6 Months in Hepatic Proton Density Fat Fraction (PDFF%), Assessed by 1H-Magnetic Resonance Spectroscopy (1H-MRS)

    Time frame: Baseline, Month 6

  8. Annualized Frequency of Rhabdomyolysis-MCEs and Cardiomyopathy-MCEs

    Time frame: Up to Year 4

  9. Annualized Duration of Rhabdomyolysis-MCEs, Cardiomyopathy-MCEs, and Hypoglycemic-MCEs

    Time frame: Up to Year 4

  10. Change From Baseline in Caregiver-reported Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scale Score for Participants 2 Years of Age or Older

    Time frame: Up to Year 4

  11. Change From Baseline in PedsQL Infant Scale Score for Participants Ages 1 to <24 Months

    Time frame: Up to Year 4

  12. Survival Time

    Time frame: Up to Year 4

  13. Annualized Hospitalization Days

    Time frame: Up to Year 4

  14. Number of Missed School or Learning Opportunity Days

    Time frame: Up to Year 4

  15. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs)

    Time frame: Up to Year 4

  16. Number of Participants With TEAEs and Serious TEAEs Leading to Dose Modifications, Dose Reductions, Treatment Interruptions, Discontinuations From Study Drug, and Discontinuations From the Study

    Time frame: Up to Year 4

  17. Plasma Concentration Levels of Heptanoate

    Time frame: Up to Year 1

  18. Plasma Concentration Levels of Beta Hydroxypentanoate (BHP)

    Time frame: Up to Year 1

  19. Acceptability and Palatability Survey Scores of Triheptanoin Mixed with Oral Liquids

    Time frame: Up to Year 1

07

Study locations

15 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Aug 2027, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Jul 6, 2023
StartActual
Feb 28, 2023
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05933200
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Feb 28, 2023
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Medical Director
study director · Ultragenyx Pharmaceutical Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triheptanoin

Start the discussion